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Abstract
Background: Thoracic paravertebral block (TPVB) is used to reduce pain after breast cancer surgery (BCS), but the
pain-reduction effects more than 1 year after surgery are unclear.
Findings: Fifty-one patients underwent BCS at the Niigata City General Hospital from December 2009 through
March 2010. To evaluate the long-term effects of TPVB in the reduction of chronic pain after BCS, we retrospectively
reviewed the anesthesia charts and medical records of these patients and conducted telephone surveys regarding
postoperative pain 13–17 months after surgery in 46 of these patients. Among the 46 patients enrolled in this
study, 17 experienced chronic pain. There was a significant difference in the percentage of patients that received
TPVB among those with and without chronic pain (patients with chronic pain 5/17 (29.4 %), patients without
chronic pain 18/29 (62.1 %), p = 0.039). The pain score 3–6 h after surgery was significantly higher in the patients
with chronic pain than without (p = 0.016). Bivariate logistic regression revealed that TPVB and pain score 3–6 h
after surgery were independent predictive factors of chronic pain after BCS.
Conclusions: These results indicate that TPVB has the potential to reduce chronic pain for more than 1 year
after BCS.
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Introduction
Breast cancer is the most commonly diagnosed malig-
nancy in women, and the incidence of this condition is
increasing [1, 2]. Because of the desirability of breast-
conserving surgical techniques and the use of sentinel
lymph node sampling, less invasive breast cancer surgery
(BCS) procedures have been developed [3–5]. However,
after BCS, up to 80 % of patients experience chronic
postoperative pain [6, 7]. The exact cause of chronic
postoperative pain after BCS remains unclear, but there
is an association between acute pain and chronic pain
generation after BCS [8–11].
Thoracic paravertebral block (TPVB) is a commonly
used adjuvant analgesic technique in BCS, and previous
study reported that TPVB reduces intraoperative anal-
gesic requirements and suppresses acute postoperative
pain [12, 13]. However, the influence of TPVB on
chronic postoperative pain after BCS remains controver-
sial [14–16].
We hypothesized that TPVB combined with general
anesthesia may reduce acute and chronic postoperative
pain after BCS. We analyzed the association between the
incidence of chronic postoperative pain after BCS and
the use of TPVB combined with general anesthesia by
using a retrospective chart review and telephone survey.
Case series
Study subjects
This retrospective cohort study was performed at Nii-
gata City General Hospital. This study was reviewed and
approved by the Niigata City General Hospital institu-
tional review board (approval number 14–047). Written
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informed consent was obtained from the patient, and we
confirmed the consent for publication of this case series
when we performed telephone survey to the patients.
We reviewed the anesthesia charts and medical records
of all patients who underwent BCS under general
anesthesia with or without TPVB from December 2009
through March 2010. Patients who underwent bilateral
BCS or simultaneous BCS and surgery involving another
part of the body were excluded. The same anesthesiologist
(HS) performed TPVB with general anesthesia in all pa-
tients. The director of the division (SD) assigned the
anesthesia cases of the day to an individual anesthesiologist,
and certain types of cases were not assigned to a specific
individual.
Analgesia and data collection
General anesthesia was induced with propofol and remi-
fentanil and maintained with propofol or sevoflurane
and remifentanil. The propofol infusion rate was regulated
by target-controlled infusion (target blood concentration
1.8–4.0 μg/ml with Terumo TE372 TCI [Diprifusor]). The
patients were monitored using an electrocardiogram, non-
invasive arterial blood pressure (every 5 min), pulse oxim-
eter, and bispectral index™ (BIS™) monitor (Aspect Medical
Systems, Leiden, The Netherlands). Target BIS values were
set between 40 and 60. We adjusted the remifentanil dose
to maintain systolic blood pressure of 80–140 mmHg,
heart rate of 50–100 beats/min, and BIS values of 40–60.
TPVB was performed under ultrasound guidance before
induction of general anesthesia by administering 20-ml
0.375 or 0.5 % ropivacaine in one or two intercostal spaces
between T2/3 and T4/5. Non-TPVB patients received fen-
tanyl and flurbiprofen axetil as transitional analgesia.
The medical records were reviewed by an anesthesiologist
(HN) blinded to the anesthesia method to determine the
intensity of postoperative pain at 0–3, 3–6, and 6–24 h after
surgery according to a four-point verbal rating scale
(0: none, 1: mild pain, 2: moderate pain, 3: severe
pain). Flurbiprofen axetil, loxoprofen, and acetamino-
phen were used as rescue analgesics.
An anesthesiologist (HN) interviewed the patients by
phone to determine the postoperative pain 13–
17 months after surgery. Chronic pain was defined as
pain in the surgical area or the ipsilateral arm, present at
least 4 days a week, with an intensity of one or more on
the four-point verbal rating scale, described as a typical
neuropathic pain consisting of burning pain, shooting
pain, pain evoked by pressure, and deep blunt pain [17].
We recorded patient age, height, weight, body mass
index (BMI), surgical procedure, intraoperative average
remifentanil dose and analgesia (with or without TPVB),
postoperative acute pain within 24 h, postoperative adju-
vant chemotherapy and radiotherapy, duration from sur-
gery to telephone survey, and cancer recurrence. We
evaluated which parameters were correlated with chronic
postoperative pain.
Data analyses
Data for continuous variables are presented as the
mean ± SD; data for categorical or ordinal variables,
and data that did not conform to a normal distribution,
are presented as the median [range]. Demographic data
were analyzed by paired t test or one-way analysis of vari-
ance (ANOVA). Univariate analyses were performed using
the Mann–Whitney U test or Fisher’s exact test. All statis-
tical analyses were performed using Microsoft Excel 2011
for Macintosh (Microsoft, Redmond, WA, USA) with a
statistical macro (XLSTAT2014; Addinsoft, New York,
NY, USA). We considered p < 0.05 statistically significant.
Results
Fifty-one patients underwent BCS during the study
period. After exclusion of patients who underwent bilat-
eral breast surgery or simultaneous surgery involving an-
other body part, we identified 49 patients as a telephone
survey conducted in May 2011. The telephone survey
was conducted in May 2011 and 46 patients answered
the survey completely (Fig. 1).
We used 0.375 % ropivacaine for 3 cases and 0.5 %
ropivacaine for 17 cases. There was no difference in the
average dose of remifentanil during surgery (0.375 %
0.068 ± 0.011 μg/kg/min vs. 0.5 % 0.064 ± 0.016 μg/kg/
min). Therefore, we pooled the data for patients treated
with the two concentrations of ropivacaine. The average
dose of remifentanil was significantly lower in the patients
with TPVB than in those without (0.064 ± 0.016 μg/kg/
min vs. 0.124 ± 0.064 μg/kg/min, p < 0.0001; Fig. 2).
The interval between surgery and the telephone survey
ranged from 13 to 17 months. Seventeen of 46 (37 %)
patients suffered chronic postoperative pain. We com-
pared the demographic data, anesthetic method, postop-
erative pain score, and perioperative adjuvant cancer
therapy between patients with and without chronic pain
(Table 1). There were no significant differences in pa-
tient characteristics, operative procedure, duration since
the operation, postoperative acute pain within 24 h after
surgery, and the incidence of required rescue analgesics
between the patients with and without chronic pain. The
percentage of patients that received TPVB was signifi-
cantly smaller among those with chronic pain than
among those without (5/17 (29.4 %) vs. 18/29 (62.1 %),
p = 0.039). However, there was no difference in the worst
pain score within 24 h of surgery between the two
groups (p = 0.33). The pain scores 3–6 h after surgery
were significantly higher for those with chronic pain
than those without. The pain scores 0–3 and 6–24 h
after surgery were not significantly different between the
two groups (Fig. 3). On the other hand, we compared 23
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patients who received TPVB with the other 23 patients
who did not receive TPVB about postoperative pain
score. The pain scores recorded during the first 24 h
after surgery tended to be lower for those who received
TPVB than for those who did not (0–3 h; p = 0.076, 3–
6 h; p = 0.056, 6–24 h; p = 0.048). Moreover, incidence of
chronic pain was significantly lower in the patients who
received TPVB than the patients who did not received
(21.7 % [5/23] vs. 52.2 % [12/23]).
Discussion
Study results revealed that TPVB combined with general
anesthesia reduced the occurrence of postoperative
chronic pain for more than 1 year after BCS and that
postoperative acute pain 3–6 h after surgery was a posi-
tive predictive factor for chronic postoperative pain.
We defined chronic postoperative pain as intermittent
pain more than 4 days in a week [17], and the incidence
(37 %) was in accordance with previous reports [6, 7].
Compared with general anesthesia alone, TPVB com-
bined with general anesthesia enhances recovery after
surgery [12, 13]. However, there are few reports on the
effects of TPVB on chronic pain after mastectomy [14,
15]. In one study, TPVB with general anesthesia reduced
the severity of chronic pain, although it failed to reduce
the relative risk of chronic pain, up to 6 months after
modified radical mastectomy [16]. In our study, TPVB
reduced postoperative chronic pain for more than 1 year
after surgery, as previously reported [15].
Mechanisms whereby TPVB prevents chronic pain
after BCS remain unknown, but cumulative evidence
suggests that the intensity of acute postoperative pain is
Fig. 1 CONSORT diagram of this study
Fig. 2 Average doses of remifentanil administered during breast
cancer surgery in patients with or without TPVB. In patients with
TPVB, the remifentanil doses were significantly smaller than in those
without TPVB
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Table 1 Demographic data and postoperative outcomes
Chronic pain (n = 17) No chronic pain (n = 29) p value
Age (years) 55.7 ± 11.7 57.4 ± 12.4 0.78
Height (cm) 156.2 ± 6.9 155.3 ± 6.0 0.60
Body weight (kg) 56.8 ± 10.9 55.7 ± 9.1 0.82
Body mass index 23.3 ± 4.0 23.1 ± 3.1 0.97
Type of surgery
Lumpectomy 10 13 0.38
Mastectomy 7 16
No. of axillary lymph nodes removed 4 5 0.71
Treatment received
Surgery alone 16 26
Surgery + radiation 0 1 1
Surgery + chemotherapy 0 1
Surgery + radiation + chemotherapy 1 1
Postsurgery (months) 15.2 ± 1.4 14.7 ± 1.3 0.18
No. of perioperative thoracic paravertebral nerve blocks 5 18 0.039
Postsurgery acute pain (<24 h)
Severe 2 (11.8 %) 0 (0 %)
Moderate 6 (35.3 %) 9 (31.0 %) 0.33
Mild 5 (29.4 %) 11 (37.9 %)
None 4 (23.5 %) 9 (31.0 %)
Incidence of rescue analgesics 1 [0–4] 0 [0–3] 0.23
No. of cancer recurrence 0 0 1
Data are shown as mean ± SD or median [range]
Fig. 3 Patient distribution of postoperative pain scores 0–3, 3–6, and 6–24 h after surgery in patients with and without chronic pain. The pain
score 3–6 h after surgery was significantly higher in the patients with chronic pain than in the patients without chronic pain. However, there was
no significant difference in the pain scores 0–3 and 6–24 h after surgery between the two groups, although the patients with chronic pain
tended to experience more pain than the patients without chronic pain at each time interval
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associated with the incidence of chronic pain [8–11, 18].
In this survey, the pain score 3–6 h after surgery was
significantly less in patients without chronic pain than in
those with chronic pain. In previous studies, preopera-
tive TPVB in BCS reduced the postoperative pain scores
and the requirement for supplemental analgesics for at
least 24 h after surgery [12, 13]. Moreover, regional
anesthesia preceding surgery reduced the progression of
postoperative pain and the requirement for supplemen-
tal analgesia [19], which is consistent with our findings.
This study has certain limitations. First, it is retro-
spective, and a prospective randomized study is needed.
Second, there was no difference in the worst pain score
within 24 h after the surgery between the two groups.
On the other hand, the pain scores 6–24 h after surgery
were significantly lower for those with TPVB than those
without, even though we did not find a statistically
significant difference in the pain scores at 0–3 h or at 3–
6 h. In the patients who received TPVB, we did not
perform cold or pin-prick tests, but the intraoperative
remifentanil requirement was significantly less in the
patients who received TPVB than in patients who did
not. Hence, we can assume that TPVB was effective.
Moreover, in the patients who received TPVB, fentanyl
was not administered, as it was in those who did not re-
ceive TPVB (average dose, 1.55 ± 1.11 μg/kg), resulting
in comparable pain scores 0–3 h after surgery between
the two groups(Fig. 3). In addition, TPVB does not block
the brachial plexus nerve; therefore, neither the pectoral
nerve nor the long thoracic nerve would be blocked by
TPVB. These regional deficiencies of analgesia are pre-
sumed to have affected the finding that there was no dif-
ference in the worst pain score within 24 h after the
surgery between the two groups. Third, the patients re-
cruited for this survey were heterogeneous and under-
went different types of BCS. This heterogeneity might
have affected the future occurrence of chronic pain.
Fourth, the sample size was small.
Conclusions
In conclusion, results of our study suggest that TPVB
combined with general anesthesia may reduce the inci-
dence of postoperative chronic pain for more than 1 year
after BCS.
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